Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature

Shoji Saito; Ryu Yanagisawa; Kentaro Yoshikawa; Yumiko Higuchi; Terutsugu Koya; Kiyoshi Yoshizawa; Miyuki Tanaka; Kazuo Sakashita; Takashi Kobayashi; Takashi Kurata; Koichi Hirabayashi; Yozo Nakazawa; Masaaki Shiohara; Yoshikazu Yonemitsu; Masato Okamoto; Haruo Sugiyama; Kenichi Koike; Shigetaka Shimodaira

doi:10.1016/j.jcyt.2014.10.003

Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature

Cytotherapy. 2015 Mar;17(3):330-5. doi: 10.1016/j.jcyt.2014.10.003. Epub 2014 Dec 4.

Authors

Shoji Saito¹, Ryu Yanagisawa¹, Kentaro Yoshikawa¹, Yumiko Higuchi², Terutsugu Koya², Kiyoshi Yoshizawa², Miyuki Tanaka³, Kazuo Sakashita³, Takashi Kobayashi², Takashi Kurata³, Koichi Hirabayashi³, Yozo Nakazawa³, Masaaki Shiohara³, Yoshikazu Yonemitsu⁴, Masato Okamoto⁵, Haruo Sugiyama⁶, Kenichi Koike³, Shigetaka Shimodaira⁷

Affiliations

¹ Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan; Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
² Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan.
³ Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
⁴ R&D Laboratory for Innovative Biotherapeutics, Kyushu University Graduate School of Pharmaceutical Sciences, Fukuoka, Japan.
⁵ Department of Advanced Immunotherapeutics, Kitasato University School of Pharmacy, Tokyo, Japan.
⁶ Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan.
⁷ Center for Advanced Cell Therapy, Shinshu University Hospital, Matsumoto, Japan. Electronic address: shimodai@shinshu-u.ac.jp.

PMID: 25484308
DOI: 10.1016/j.jcyt.2014.10.003

Abstract

A 15-year-old girl with acute lymphoblastic leukemia received allogeneic dendritic cell vaccination, pulsed with Wilms tumor 1 (WT1) peptide, after her third hematopoietic stem cell transplantation (HSCT). The vaccines were generated from the third HSCT donor, who was her younger sister, age 12 years. The patient received 14 vaccines and had no graft-versus-host disease or systemic adverse effect, aside from grade 2 skin reaction at the injection site. WT1-specific immune responses were detected after vaccination by both WT1-tetramer analysis and enzyme-linked immunosorbent spot assay. This strategy may be safe, tolerable and even feasible for patients with a relapse after HSCT.

Keywords: ELISPOT; HSCT; Wilms tumor 1; dendritic cells; tetramer analysis.

Publication types

Case Reports
Clinical Trial, Phase I
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Cancer Vaccines / adverse effects*
Cancer Vaccines / immunology
Cancer Vaccines / therapeutic use
Child
Dendritic Cells / immunology
Dendritic Cells / transplantation*
Female
Graft vs Host Disease / immunology
Hematopoietic Stem Cell Transplantation / methods*
Humans
Male
Neoplasm Recurrence, Local / immunology
Neoplasm Recurrence, Local / therapy
Peptide Fragments / administration & dosage*
Peptide Fragments / immunology
Peptide Fragments / therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Safety
T-Lymphocytes / immunology*
Tissue Donors
Vaccination / adverse effects
WT1 Proteins / administration & dosage*
WT1 Proteins / immunology
WT1 Proteins / therapeutic use

Substances

Cancer Vaccines
Peptide Fragments
WT1 (126-134), human
WT1 Proteins